LGD-4033 (Ligandrol) — Strongest SARM by Dragon Pharma
LGD-4033 (Ligandrol, VK5211) is Dragon Pharma's formulation of the most anabolically potent widely available SARM at 15mg per tablet — developed by Ligand Pharmaceuticals and subsequently licenced to Viking Therapeutics. LGD-4033 has completed Phase I human clinical trials, providing genuine human pharmacokinetic and lean mass data at doses far below typical performance use. It produces significantly greater lean mass gains than Ostarine at equivalent doses, with correspondingly greater HPG axis suppression — the most important trade-off to understand when positioning LGD-4033 within the SARM hierarchy.
Also searched as: LGD-4033 Ligandrol, LGD 4033 15mg, Ligandrol Dragon Pharma, VK5211, Ligandrol SARM tabs.
The Phase I Clinical Trial Data
LGD-4033 has more rigorous human clinical evidence than most SARMs — but the data needs careful interpretation for performance use:
- Basaria et al. (2010, Journal of Gerontology) conducted a Phase I ascending-dose study in 76 healthy young men — randomised to placebo or LGD-4033 at 0.1mg, 0.3mg or 1.0mg/day for 21 days. Results: dose-dependent increases in lean body mass (0.3kg at 0.1mg, 0.6kg at 1.0mg over 21 days); significant dose-dependent decreases in total testosterone, SHBG, LH and FSH; and fat mass reductions at higher doses
- The key clinical finding: at just 1.0mg/day for 21 days, LGD-4033 produced meaningful lean mass gains and significant HPG suppression. Performance users typically use 5-15mg/day — doses 5-15× higher than the clinical trial maximum, for cycle lengths 4-6× longer
- No prostate-specific effects (PSA) were observed at clinical doses — consistent with SARM tissue selectivity. No significant liver enzyme elevation at clinical doses — though performance doses and durations exceed the clinical trial parameters
- Recovery after the 21-day clinical trial: testosterone, SHBG, LH and FSH returned to baseline within 5 weeks of cessation at 1mg/day dose — suggesting HPG recovery at clinical doses, though performance doses produce more substantial suppression with potentially longer recovery
LGD-4033 vs Ostarine — The SARM Potency Comparison
Understanding LGD-4033 requires understanding how it differs from Ostarine (MK-2866), the most commonly referenced SARM:
| Parameter | LGD-4033 (Ligandrol) | Ostarine (MK-2866) |
|---|---|---|
| Anabolic potency | High — significantly stronger | Mild-moderate |
| Lean mass gains | 3–5 kg in 8-week cycle typical | 1–3 kg in 8-week cycle typical |
| Suppression degree | Significant — testosterone suppression substantial | Mild — 20-40% LH/FSH reduction |
| Clinical human data | Phase I data at 0.1-1.0mg/day | Phase III data (3mg/day, cancer cachexia) |
| PCT required | Yes — standard PCT advisable for all cycles | Advisable for 8+ week cycles at 25mg |
| Bone density effects | Yes — high AR affinity in bone tissue | Some — documented in clinical data |
| Best use case | Mass building; strength; recomposition | Lean mass preservation; injury support; first SARM |
The Suppression Reality at Performance Doses
LGD-4033's suppression at performance doses (5-15mg/day) is substantially greater than at clinical doses (0.1-1.0mg/day) and requires honest discussion:
- At 5mg/day for 8 weeks, user-reported testosterone suppression of 50-70% from baseline is commonly documented — significantly greater than Ostarine's typical 20-40%
- At 10-15mg/day, near-complete LH and FSH suppression is reported by many users — with testosterone falling to very low levels, requiring the same attentiveness to PCT as after an injectable AAS cycle
- The 24-36 hour half-life means once-daily dosing produces stable blood levels, but also means the compound is continuously suppressive throughout the cycle with no "recovery days"
- PCT timing: LGD-4033 has a 24-36 hour half-life — PCT can begin 24-48 hours after the last tablet, similar to Ostarine. A standard 4-6 week PCT with Clomid or Nolvadex is advisable after cycles of 8+ weeks at standard performance doses
LGD-4033 in the Full SARM Comparison
| SARM | Anabolic Potency | Suppression | Clinical Data | Best Application |
|---|---|---|---|---|
| LGD-4033 | Highest available | Significant | Phase I human trial | Mass; strength; recomposition |
| MK-2866 (Ostarine) | Mild-Moderate | Mild | Phase III human trial | Lean mass; injury; first SARM |
| YK-11 | Very high | Significant | Preclinical only | Myostatin inhibition; strength |
| S23 | High | High | Preclinical only | Cutting; hardness |
Effects and Benefits
- Highest anabolic potency among widely available SARMs — 3-5kg lean mass gains in a typical 8-week performance cycle
- Significant strength increases — AR activation in muscle tissue drives protein synthesis and neuromuscular efficiency
- Bone density support — LGD-4033 has demonstrated bone mineral density effects in clinical models, making it relevant for injury prevention and bone health
- No aromatisation — no direct estrogenic side effects from LGD-4033 itself
- Oral — no injection required
Dosage and Administration
| Experience Level | Daily Dose | Cycle Length | PCT |
|---|---|---|---|
| First LGD cycle | 5 mg/day (⅓ tablet) | 6–8 weeks | 4-week Clomid/Nolvadex |
| Standard performance | 10 mg/day (⅔ tablet) | 8 weeks | 4-6 week PCT |
| Advanced | 15 mg/day (1 tablet) | 8 weeks | 6-week PCT advisable |
At 15mg per tablet, the standard 10mg performance dose requires splitting the tablet (⅔). The 24-36 hour half-life supports once-daily dosing — morning or evening both work. At the full 15mg tablet dose, suppression is pronounced and PCT is as important as after an injectable AAS cycle. Never stack with other suppressive compounds without understanding the additive suppression.
PCT for LGD-4033
- Clomid — 50mg/day for 2 weeks, then 25mg/day for 2 weeks; start 24-48 hours after last LGD tablet
- Nolvadex — 40mg/day for 2 weeks, then 20mg/day for 2 weeks; same timing
- At 10-15mg/day cycles, a 6-week PCT may be warranted given the more significant suppression compared to Ostarine
LGD-4033 in a Stack
- MK-677 — oral GH secretagogue adds GH/IGF-1 elevation to LGD-4033's AR-driven anabolic effects; a fully injectable-free mass and recovery stack
- GW-501516 (Cardarine) — PPARδ endurance support alongside LGD-4033's mass building; addresses the cardiovascular and endurance demands of high-volume mass training
"LGD-4033 is the strongest anabolic SARM available — Phase I human trial data confirms meaningful lean mass gains at just 1mg/day, with dose-dependent suppression that at performance doses (5-15mg/day) requires the same PCT attentiveness as an injectable AAS cycle."
Storage and Handling
Store LGD-4033 at room temperature, away from direct sunlight and moisture. Keep in original packaging until use.
